Phase II clinical trial of carboplatin in canine transitional cell carcinoma of the urinary bladder

J Vet Intern Med. Sep-Oct 1997;11(5):279-83. doi: 10.1111/j.1939-1676.1997.tb00465.x.

Abstract

Fourteen dogs with histologically-confirmed transitional cell carcinoma (TCC) of the urinary bladder were treated with 300 mg/m2 carboplatin every 3 weeks. Response to therapy was assessed with abdominal radiography, double contrast cystography, urinary bladder ultrasonography and thoracic radiography before therapy and at 6-week intervals during therapy. Dogs were monitored for hematologic toxicity with a CBC and platelet count performed immediately before and 10 to 14 days after carboplatin treatment. Tumor responses included progressive disease in 11 dogs and stable disease in 1 dog. Two dogs were euthanized due to carboplatin toxicity before assessment of tumor response. Toxicity included thrombocytopenia with or without neutropenia in 7 dogs and gastrointestinal toxicity in 6 dogs. Carboplatin therapy was not beneficial in the treatment of TCC in the 14 dogs in this study.

Publication types

  • Clinical Trial
  • Clinical Trial, Phase II
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / pharmacokinetics
  • Antineoplastic Agents / therapeutic use*
  • Carboplatin / adverse effects
  • Carboplatin / pharmacokinetics
  • Carboplatin / therapeutic use*
  • Carcinoma, Transitional Cell / drug therapy
  • Carcinoma, Transitional Cell / pathology
  • Carcinoma, Transitional Cell / veterinary*
  • Dog Diseases / diagnostic imaging
  • Dog Diseases / drug therapy*
  • Dog Diseases / pathology
  • Dogs
  • Dose-Response Relationship, Drug
  • Female
  • Incidence
  • Male
  • Neutropenia / chemically induced
  • Neutropenia / epidemiology
  • Neutropenia / veterinary
  • Radiography, Abdominal / methods
  • Radiography, Abdominal / veterinary
  • Radiography, Thoracic / veterinary
  • Thrombocytopenia / chemically induced
  • Thrombocytopenia / epidemiology
  • Thrombocytopenia / veterinary
  • Ultrasonography
  • Urinary Bladder / diagnostic imaging
  • Urinary Bladder / drug effects
  • Urinary Bladder / pathology
  • Urinary Bladder Neoplasms / drug therapy
  • Urinary Bladder Neoplasms / pathology
  • Urinary Bladder Neoplasms / veterinary*

Substances

  • Antineoplastic Agents
  • Carboplatin